Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
 
Register now or login to post to this thread.

Hutchison China Meditech (HCM)     

dreamcatcher - 07 Aug 2012 21:04




Hutchison China MediTech Limited ("Chi-Med") is a China-based globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products.

Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.

Chi-Med is listed on the London Stock Exchange’s AIM market (AIM: HCM). It is majority owned by CK Hutchison Holdings Limited (SEHK: 0001), a leading international conglomerate committed to innovation and technology with over a quarter of a million employees in more than 50 countries and annual sales of over US$50 billion.

http://www.chi-med.com/eng/global/home.php


free counters
Chart.aspx?Provider=EODIntra&Code=HCM&SiChart.aspx?Provider=EODIntra&Code=HCM&Si

dreamcatcher - 07 Aug 2012 21:24 - 2 of 186

2012 Interim Report - ended 30th June 2012

http://www.chi-med.com/eng/irinfo/reports/2012ir.pdf

dreamcatcher - 07 Aug 2012 21:28 - 3 of 186

Chi-Med operating profits up 97%
StockMarketWire.com
Operating profits at Hutchison China MediTech jumped by 97% to $7.2m in the six months to the end of June.

Revenues were up 25% at $102.9m and there was a net profit attributable to Chi-Med equity holders of $2.5m compared with a loss of $0.7m a year ago.

Chief executive Christian Hogg said: "This has been another good half year.

"Revenues on continuing operations are up 25%, sustaining our top-line growth, operating profit almost doubled and net profitattributable to Chi-Med equity holders is $2.5 million, compared to a loss in the same period last year. Our outlook is promising.

"We are one of the leading innovators in the China pharmaceutical industry, having invested almost $130 million in drug research and development in the field of oncology and immunology over the past eleven years.

"We believe the fruits of this investment are set to emerge over the coming few years, and are set to transform the group."


dreamcatcher - 10 Sep 2012 23:02 - 4 of 186

Drifted down back end of Aug, recovering well in Sept.

dreamcatcher - 13 Sep 2012 18:11 - 5 of 186

..Hutchison China Meditech director tops up stake

Sharecast – 55 minutes ago

......
LONDON (ShareCast) - Michael Howell, an Independent Non-Executive Director at Hutchison China Meditech, a research and development company majority-owned by Chi-Med, purchased 31,800 shares at 435.00p each on Tuesday.

The £138,330 transaction, which takes Howell's interest in the company to 153,600 shares, comes six weeks after the firm unveiled a strong first half.

During the six months ended June 30th, Hutchison saw pre-tax profits almost doubled to $6.5m on revenues of $109.2m, and said it was well-positioned to take advantage of the enormous Chinese market.

The firm said profits had been spurred on by the rapid expansion of domestic consumer spending power in China.

The AIM 100-listed company has seen a 25% increase in its share price over the past year, equal to 85p.

Towards the end of August the company announced Panmure Gordon as its new financial advisor after its old one, Lazard, stopped its nominated advisory services.


dreamcatcher - 01 Nov 2012 07:38 - 6 of 186

Phase I trial with EGFR inhibitor theliatinib
RNS
RNS Number : 9475P
Hutchison China Meditech Limited
01 November 2012









Hutchison China MediTech Limited ("Chi-Med")
(AIM: HCM)


Hutchison MediPharma Limited initiates Phase I clinical study
with its novel EGFR inhibitor Theliatinib


London: Thursday, 1 November 2012: Chi-Med announced that Hutchison MediPharma Limited ("HMP"), its majority owned R&D company, initiated the first-in-human Phase I clinical trial of Theliatinib (HMPL-309). This is the fourth oncology compound from the internal discovery programmes of HMP to enter into clinical development in China. Theliatinib is a novel, orally active small molecule inhibitor targeting the wild type epidermal growth factor receptor ("EGFR") or resistant EGFR tumours. The first patient was dosed on 30 October 2012.

The primary objectives of the Phase I study are to evaluate its safety and tolerability in patients with advanced solid tumours and to determine its maximum tolerated dose. This study will also evaluate its preliminary efficacy against non-small cell lung cancer ("NSCLC"), determine the pharmacokinetics of Theliatinib under single dose and repeat doses and explore the relationship between the Theliatinib's activity and certain biomarkers.

In pre-clinical studies, Theliatinib demonstrated strong anti-tumour activity against EGFR wild type tumours at doses that are expected to be well tolerated. Theliatinib was also found to have good pharmacokinetic properties and a favourable safety profile. These studies also exhibited good tissue distribution and stronger anti-tumour activity in EGFR wild type and EGFR resistant tumours, compared with first generation small molecule EGFR inhibitors. "If these attributes are also demonstrated in clinical studies, we believe that Theliatinib could become an important therapy in this area," said Christian Hogg, Chief Executive Officer of Chi-Med.

Ends

Enquiries

dreamcatcher - 01 Nov 2012 14:34 - 7 of 186

Hutchison initiates phase 1 on Theliatinib trial
Thu 01 Nov 2012

HCM - Hutchison China Meditech Ltd



LONDON (SHARECAST) - Pharmaceutical company Hutchison China MediTech (Chi-MEd) has announced that through its majority-owned research and development company it has initiated the first-in-human phase 1 clinical trial of its Theliatinib (HMPL-309) product.

The firm said the main aim of the study is to evaluate its safety and tolerability in patients with advanced solid tumours and to determine its maximum tolerated dose.

The trial is the fourth oncology compound from the internal discovery programmes the R&D company to enter into clinical development in China.

Theliatinib is an orally active product which targets the wild type epidermal growth factor receptor (EGFR) or resistant EGFR tumours.

Phase 1 will also evaluate its preliminary efficacy against non-small cell lung cancer (NSCLC), determine the way the body responds to Theliatinib under single dose and repeat doses and explore the relationship between the Theliatinib's activity and certain biomarkers.

"In pre-clinical studies, Theliatinib demonstrated strong anti-tumour activity against EGFR wild type tumours at doses that are expected to be well tolerated," the company said.

"These studies also exhibited good tissue distribution and stronger anti-tumour activity in EGFR wild type and EGFR resistant tumours, compared with first generation small molecule EGFR inhibitors. If these attributes are also demonstrated in clinical studies, we believe that Theliatinib could become an important therapy in this area."

dreamcatcher - 10 Nov 2012 15:30 - 9 of 186

Hutchison China Meditech is focused primarily on China and it has three divisions- healthcare division, drug development and consumer products. Drugs are supplied over the counter or by prescription and one of Chi-Meds products is on China's essential list of medicines, of which there are only about 370. As the Chinese become more affluent , more and more people are signing up for medical insurance, while the government is increasing its investment in national health care. In the last four years there has been a 53% surge in spending to $58.7 billion , which works out an average of $142 per person. so the potential for further growth in spending is substantial within the sector.

dreamcatcher - 28 Nov 2012 07:03 - 10 of 186

Chi-Med and Nestle? Health Science Joint Venture
RNS
RNS Number : 1484S
Hutchison China Meditech Limited
28 November 2012











Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)





Chi-Med and Nestlé Health Science establish Joint Venture

'Nutrition Science Partners' intends to:


· Research and develop a pipeline of innovative gastrointestinal botanical medicines and nutritional products through access to best-in-class Traditional Chinese Medicine library and discovery platform
· Progress HMPL-004, the lead candidate, through Phase III trials for ulcerative colitis and Crohn's disease


London: Wednesday, 28 November 2012: Nestlé Health Science SA, a fully-owned subsidiary of Nestlé SA, and Chi-Med, today announce that they have agreed to form a 50/50 joint venture to be named Nutrition Science Partners Limited ("NSP").

The purpose of NSP is to research, develop, manufacture and market worldwide novel medicines and nutritional products derived from botanical plant origins. NSP will focus on gastrointestinal indications ("GI"), and may in the future expand into the metabolic disease and brain health areas.

Luis Cantarell, President and CEO of Nestlé Health Science said: "This JV provides Nestlé Health Science with an opportunity to develop and commercialise truly innovative and scientifically validated botanical based nutrition solutions for personalised healthcare in gastrointestinal health. Whilst Nestlé Health Science will bring unique competencies in nutritional sciences, diagnostics and commercial capabilities, Chi-Med will provide their best-in-class Traditional Chinese Medicine library and discovery platform, which will be the basis of NSP's future GI pipeline. The lead candidate HMPL-004 addresses key unmet GI needs for IBD patients."

Christian Hogg, CEO of Chi-Med, said: "Chi-Med has invested for many years in developing novel medicines for the global market derived from proven botanical sources. We are today a leading company in the world in this field. We are now joined in this important endeavour by Nestlé Health Science, and are confident that by harnessing the resources of our two groups, we will succeed in bringing a stream of novel botanical medicines and nutritional products to market and in-so-doing build significant value for patients and for our shareholders."

Nestlé Health Science will make an initial capital investment in return for its 50% shareholding in NSP; while Chi-Med will provide exclusive rights to its extensive botanical library and well-established botanical R&D platform, in the field of gastrointestinal disease. Such botanical library contains over 1,500 purified natural products and over 50,000 extracts/fractions derived from more than 1,200 different medicinal plants.

NSP will also progress HMPL-004, a novel, oral therapy for Inflammatory Bowel Disease ("IBD") developed by Hutchison MediPharma Limited ("HMP") and derived from a botanical extract, through Phase III registration trials for ulcerative colitis and Crohn's disease. The clinical efficacy and safety of HMPL-004 in the treatment of IBD has already been demonstrated in over 400 patients, including successful Phase IIb trials completed by HMP in North America and Europe. The Phase III program for HMPL-004 is scheduled to start in early 2013. It will be conducted primarily in the US and Europe and is expected, in total, to enrol over 2,700 patients suffering from ulcerative colitis and Crohn's disease.

NSP will be governed by its Board. Luis Cantarell will be the Chairman, and Christian Hogg will be both a Director and the first General Manager of NSP.

NSP will be funded primarily through the initial Nestle Health Science capital investment and further milestone payments linked to success of clinical and commercial activities.

This transaction is subject to regulatory approval.



Ends

dreamcatcher - 29 Nov 2012 10:58 - 11 of 186

Hutchison China Meditech: UBS raises target price from 470p to 520p and reiterates its buy recommendation.

dreamcatcher - 11 Jan 2013 22:23 - 13 of 186

Whats new - Major deal with Nestle, phase lll trials due to start, FDA looking favourably at botanical medicines.

The surge in HCM's shareprice inthe first quarter of last year signalled that the market had started to understand how important the company's access to the Chinese medical market could be in years to come.Nestle seems to have recognised the importance of HCM's research into plant-derived medicines by forming a joint venture (JV) with the company. The jv will allow the company's main product, HMPL-004, a treatment for gastroin-testinal problems, to go into phase lll clinicaltrials, with the potential commercialisation around the world to follow. The trials start early this year and will involve more than 2,700patients.

dreamcatcher - 24 Jan 2013 15:00 - 14 of 186

Upgrades to follow earnings and portfolio developments - Analysts believe the company will grow sales at a compound clip of some 12.3% a year out to 2014 and thus outpace its target markets. This progress will be partly driven by positive newsflow from Chi-Meds oncology portfolio and its volitnib cancer treatment. Its UK division should also perform well, with operating profits predicted to increase by as much as $2 million. Other areas to watch include the £230 million caps joint venture formed with food giant Nestle last November to develop and market medicines and nutritional products.
Chi-meds financial statements already look healthy. In the first half of the year its unaudited revenues increased 25% year-on-year to $102.9 million,while its operating profit jumped almost 100% to $7.2 million, the firm also has $26.5 million in net cash on the balance sheet.

dreamcatcher - 26 Jan 2013 18:28 - 15 of 186

Just read the headline in IC that Biotech is back and that it could pay investors to give the sector some serious attention. The sector is waking up due to large pharma companies are closing down and outsourcing more of the research and development and concentrating on the eventual product instead. So another way of playing the trend is to asses where the greatest amount of biotech investment will be over the next few years. In this case it is China that sweeps the boardas the government is commited to spending over $300bn on bioscience research in its latest five year plan.
The easiest way to access the market is via london listed companies such as Hutchinson China Meditech (HCM)

dreamcatcher - 18 Feb 2013 07:06 - 16 of 186

Notice of Results
RNS
RNS Number : 0263Y
Hutchison China Meditech Limited
18 February 2013











Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)





Notice of Announcement of 2012 Final Results





London: Monday, 18 February 2013: Chi-Med will be announcing its final results for the year ended 31 December 2012 on Tuesday, 26 March 2013. An analyst presentation will be held at 9:00 am on the same day at Citigate Dewe Rogerson, 3 London Wall Buildings, London, EC2M 5SY.

dreamcatcher - 26 Mar 2013 07:12 - 17 of 186

Final Results



Consolidated Group Results


Revenue from continuing operations up 18% to $195.4 million (2011: $165.0m).
Operating profit up 65% to $8.9 million (2011: $5.4m) - China Healthcare and Drug R&D gains partially offset by Consumer Products Division restructuring costs.
Net profit attributable to Chi-Med equity holders up 412% to $3.6million (2011: $0.7m).
Cash and cash equivalents and unutilised bank loan facilities of $85.9 million. Net cash $23.9 million.


China Healthcare Division - Increasingly significant source of profit and cash for the Group

Sales of subsidiaries and jointly controlled entities ("JCE") up 29% to $350.5million (2011: $271.0m). Organic expansion of own brands (up 15% to $300.0m) with prescription drug sales remaining the key driver. Growth of over-the-counter ("OTC") drug distribution business (up 351% to $50.5m).
Net profit attributable to Chi-Med equity holders up 11% to $15.5 million (2011: $14.0m).
Positive impact expected in 2013 as OTC raw material prices continue to normalise.
http://www.moneyam.com/action/news/showArticle?id=4561569

js8106455 - 26 Mar 2013 16:36 - 18 of 186

Hutchison China Meditech - Full year results interview.

Click here to listen

dreamcatcher - 26 Mar 2013 16:51 - 19 of 186

Hutchison China MediTech Ltd (HCM:LSE) set a new 52-week high during today's trading session when it reached 470.00. Over this period, the share price is up 11.07%.

dreamcatcher - 26 Mar 2013 16:53 - 20 of 186

Been waiting ages gf, must break out soon.


As of Mar 22, 2013, the consensus forecast amongst 3 polled investment analysts covering Hutchison China MediTech Limited advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Feb 22, 2012. The previous consensus forecast advised investors to purchase equity in Hutchison China MediTech Limited.


goldfinger - 26 Mar 2013 18:12 - 21 of 186

Yep flagged it up on Chart Attack.
Register now or login to post to this thread.